Oncotelic Therapeutics, Inc. (OTCQB: OTLC) has announced the completion of key Phase 2 objectives in its manufacturing automation initiative with TechForce Robotics, advancing the commercialization of an AI-powered good manufacturing practices (GMP) manufacturing services platform at SAPU Bio, the company’s 45%-owned sterile injectable cGMP manufacturing joint venture. The Phase 2 deployment expands the capabilities of Oncotelic’s proprietary PDAOAI(TM) platform across sterile manufacturing operations, electronic batch records, GMP workflow execution, cleanroom monitoring and autonomous materials movement.
The integrated platform combines PDAOAI(TM) with TechForce’s autonomous robotic systems to support intelligent pharmaceutical manufacturing, creating potential opportunities in software licensing, automation deployment, manufacturing partnerships and technology-enabled contract development and manufacturing services. This development is significant as it positions Oncotelic to potentially offer a comprehensive AI-driven solution to the pharmaceutical industry, addressing the growing need for efficiency, accuracy, and compliance in manufacturing.
Oncotelic plans to demonstrate the platform at the BIO International Convention 2026 in San Diego as it pursues broader commercialization efforts within the pharmaceutical manufacturing sector. The company’s ability to showcase this technology at a major industry event underscores its commitment to innovation and market penetration. The implications of this announcement extend beyond Oncotelic’s own operations; if successful, the platform could set a new standard for GMP manufacturing, reducing costs and improving quality control across the industry.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products, addressing high-unmet-need cancers and rare pediatric indications. The company’s CEO, Dr. Vuong Trieu, has filed over 500 patent applications and holds 75 issued patents. Oncotelic also leverages its proprietary AI-enabled PDAOAI platform for research, biomarker discovery, and regulatory processes. The company owns a 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates. This manufacturing initiative aligns with Oncotelic’s broader strategy to leverage technology for drug development and manufacturing, potentially creating new revenue streams through licensing and partnerships.
For more information, visit the full press release. The latest news and updates relating to OTLC are available in the company’s newsroom at https://nnw.fm/OTLC.
